We have seen a bit of an uptick on the merger-and-acquisition front in biotech this weekOn Monday, Stemline Therapeutics (STML) said it agreed to be acquired for nearly $700 million, which represented a buyout premium of about 150%. Tuesday, Portola Pharmaceuticals (PTLA) announced it had agreed to be bought for $1.4 billion, a 130% purchase premi...
Read the full story and get access to the Real Money Pro trading floor.
There's no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.